Developer docs
API playgroundTry for free, no card

Search company profiles

CytoTronics

Full company profile

uuid0000s4v

Namestring
CytoTronics
Legal namestring
CytoTronics, Inc.
Websiteurl
cytotronics.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

CytoTronics, Inc. was a privately held Boston-based life sciences tools company founded in 2021 as a Harvard University spin-off that developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS (Complementary Metal-Oxide-Semiconductor) microelectrode arrays embedded at the base of standard 96- and 384-well microplates. Each well contained over 100,000 nanoscale electrode-based sensors enabling thousands of simultaneous, label-free, multi-modal measurements (viability, morphology, electrophysiology, metabolism, barrier function) at single-cell resolution, with the company marketing more than 13 million sensors across its plate formats. The product family comprised the entry-level Pixel Primo single-plate reader (starting list price under $30,000), the high-throughput Pixel Octo eight-plate reader with integrated benchtop incubator, proprietary Pixel Plates as recurring consumables, and the cloud-based Pixel Pro control and analysis software, supported by vertical application modules for Neural (April 2025) and Cardiac (May 2025) research.

The company's commercial model combined direct enterprise sales, an early access/Try Before You Buy program, and scientific marketing through conferences (SLAS, ISSCR, Neuroscience), targeting pharmaceutical and biotech drug discovery teams, academic and research institutions, and stem cell/iPSC-derived cell providers, with 40+ collaborator sites across 7 countries by late 2024. CytoTronics raised $22.75M in aggregate seed funding (April 2022 and September 2024) and earned the SLAS 2024 New Product Award and R&D 100 Award in 2024. In January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets, terminating CytoTronics as an independent operating company and rolling the Pixel platform into Axion's existing MEA-focused distribution network.

Short descriptiontext

CytoTronics developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS microelectrode arrays embedded in microplates to deliver label-free, multi-modal cell measurements at single-cell resolution for pharmaceutical, biotech, and academic drug discovery customers, prior to its January 2026 acquisition by Axion BioSystems.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live-cell analysis, CMOS microelectrode arrays, drug discovery platforms, cell biology instruments, electrophysiology imaging
Industry4 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAHALAF
Imaging Sensors (CMOS/CCD/ToF/Depth)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
  • Semiconductor and Other Electronic Component Manufacturing33441
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Instruments For Meas & Testing Of Electricity & Elec Signals3825
Product category
Live-Cell Analysis Instruments
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pixel Instruments and Plates
TypeHardware Sales
Description

CytoTronics sells Pixel Primo and Pixel Octo instruments along with proprietary Pixel plates (96- and 384-well format) embedded with semiconductor microchips. Starting list price under $30K USD for Pixel Primo.

cytotronics.com
2Software/SaaS (Pixel Pro)
TypeSubscription Recurring
Description

Cloud-based Pixel Pro software for control and data analysis, likely offered as subscription or included with hardware purchase

cytotronics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Pixel Primo entry-level system
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Starting list price of under $30,000 USD for Pixel Primo single plate reader

cytotronics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Pixel
Description

Semiconductor-based platform for live cell analysis enabling high-resolution monitoring of live cells with single-cell resolution across all cell types. Includes Pixel Primo (single plate reader) and Pixel Octo (8-plate benchtop system).

cytotronics.com
+1 more record
Core offering1 text field

CytoTronics designs and commercializes the Pixel platform — semiconductor-based live-cell analysis systems that integrate CMOS microelectrode arrays into standard 96- and 384-well microplates. The platform includes the Pixel Primo single-plate reader, the Pixel Octo 8-plate high-throughput reader with integrated incubator, proprietary Pixel Plates consumables with over 100,000 nanoscale electrode sensors per well, and cloud-based Pixel Pro software. The system captures 20+ cellular parameters including viability, morphology, electrophysiology, and metabolism simultaneously, enabling drug discovery and cell biology research at single-cell resolution without labels or dyes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Captures over 100,000 measurements per well across 20+ cellular parameters
+3 more records
Product overview1 text field

CytoTronics offers the Pixel platform, a semiconductor-based live-cell analysis system for cell biology discovery. The core Pixel platform consists of Pixel Primo (entry-level single plate reader starting under $30K) and Pixel Octo (high-throughput 8-plate reader with integrated benchtop incubator), both using proprietary Pixel Plates (96- or 384-well microplates with semiconductor microchips containing over 100,000 nanoscale electrode-based sensors per well). Cloud-based Pixel Pro software enables measurement control and data analysis. The platform delivers simultaneous multi-modal readouts of cell viability, morphology, electrophysiology, metabolism, and barrier function with single-cell resolution via electrical imaging technology. Specialized application modules including Neural Application (for neurological disease and neurotoxicity research) and Cardiac Application (for cardiovascular research and cardiotoxicology) extend the platform for specific therapeutic areas.

Product and service6 records
1Pixel Primo
CategoryInstrument
Description

Entry-level single plate reader for the Pixel platform that fits in any standard cell culture incubator. Reads one 96- or 384-well Pixel plate at a time, enabling semiconductor-based live-cell analysis with thousands of multi-modal measurements per well at single-cell resolution. Targeted at biotech, pharma, and academic researchers.

2Pixel Octo
CategoryInstrument
Description

High-throughput 8-plate reader and benchtop incubator with integrated environmental control for temperature, CO2, humidity, and oxygen. Reads up to eight 96- or 384-well Pixel plates simultaneously and pairs with laboratory robotic automation for industrial-scale screening of tens of thousands of wells in parallel. Targeted at pharma and biotech screening operations.

3Pixel Plates
CategoryConsumable
Description

Proprietary 96- or 384-well microplates embedded with custom-designed semiconductor microchips at the base of each well. Each well contains over 100,000 nanoscale electrode-based sensors enabling thousands of measurements per well on any cell type, spheroid, or 3D organoid system. Consumable used with Pixel Primo and Pixel Octo instruments.

4Pixel Pro
CategorySoftware
Description

Cloud-based control and interactive analysis software for Pixel systems. Enables measurement design, experiment execution, real-time data access from anywhere, and sophisticated data analysis tools for high-dimensional live cell measurements across viability, morphology, electrophysiology, metabolism, and barrier function.

5Pixel Neural Application
CategoryApplication module
Description

First-of-its-kind application combining electrical imaging with electrophysiology to simultaneously measure neural structure and activity at scale in 96- and 384-well plates with up to 144 recording channels per well. Used for drug discovery in neurological disease, neurotoxicity research, and neurodegenerative disease applications including Parkinson's, Alzheimer's, ALS, and blood-brain barrier studies.

6Pixel Cardiac Application
CategoryApplication module
Description

Multi-modal application measuring cardiomyocyte electrical activity, contractility, and cell morphology simultaneously in a single multiplexed assay at scale in 96- and 384-well plates. Enables cardiovascular disease research and cardiotoxicology studies with real-time monitoring of acute and chronic compound responses.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active collaboration for cell supply in neurodegenerative disease and neurotoxicity research. Axol provides iPSC-derived cells used with Pixel for applications in Parkinson's, Alzheimer's disease, ALS, blood-brain barrier/CNS function, and pain research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active collaboration for cell and organoid supply requiring sophisticated cell characterization that Pixel enables for disease research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active collaboration providing neuronal cells for research applications. BrainXell cells used in Pixel applications for neural function studies and blood-brain barrier modeling.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Active collaboration for organoid supply and disease modeling applications requiring Pixel's cell characterization capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration site for cardiovascular research and cardiotoxicology applications using Pixel's Cardiac application.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration providing iPSC-derived cardiomyocytes for cardiac disease modeling and Pixel applications. Human iPSC-derived glutamatergic neurons also used for neural studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for 3D cell models (organoids/spheroids) used in cardiotoxicology and disease research with Pixel systems.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for iPSC-derived cells for cardiovascular disease research and cardiac applications using Pixel platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Ioannis Karakikes studying cardiac disease phenotypes and genetic mutations in cardiomyopathies. Stanford is part of the international PRIORITY consortium for cardio-laminopathy research.

10Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration site for research activities. CytoTronics originated from Harvard University research.

cytotronics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration site for research activities. Original research foundation was developed in Harvard labs.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

In January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets including high-density CMOS MEA technology. Co-founder Jeffrey Abbott transitioned to Vice President at Axion. Axion commercializes the technology through their existing distribution network.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Axion BioSystems manufactures multi-well MEA platforms (Maestro) for neural and cardiac activity monitoring. It is the closest direct peer in microplate-format MEA electrophysiology and is now CytoTronics' acquirer, making it both a competitor and commercial vehicle for the Pixel technology.

TypeDirect peer
Description

MaxWell Biosystems develops high-density CMOS microelectrode array chips (MaxOne, MaxTwo) for single-cell and network-level electrophysiology. It is a direct peer in CMOS-MEA technology for live-cell functional readouts with comparable single-neuron resolution.

TypeDirect peer
Description

Multi Channel Systems, a Harvard Bioscience company, supplies MEA platforms and MEA-based live-cell recording instruments used in cardiac and neural safety pharmacology. It competes head-to-head with Pixel in microplate-format electrophysiology screening.

TypeDirect peer
Description

Nanion Technologies makes planar patch-clamp and MEA instruments for ion-channel research and cardiac safety screening (e.g., CardioExcyte 96). It is a direct peer in electrophysiology instrumentation targeting the same drug-discovery and safety-pharmacology customers.

TypeDirect peer
Description

Molecular Devices (a Danaher operating company) produces high-content screening imagers and electrophysiology readers used in drug discovery. It overlaps with Pixel in label-free, high-throughput functional cell analysis for pharma research workflows.

TypeDirect peer
Description

ACEA's xCELLigence real-time cell analysis system uses impedance-based readouts in microplate formats to monitor cell viability, morphology, and proliferation. It is a direct competitor in label-free, kinetic live-cell analysis targeting the same drug-discovery and toxicology use cases as Pixel.

TypeBroad incumbent
Description

Thermo Fisher Scientific is a global life-sciences tools incumbent offering cell-analysis instruments, consumables, and informatics. It competes broadly with Pixel through its laboratory products division for pharma and academic research budgets.

TypeBroad incumbent
Description

Sartorius provides cell-analysis and bioprocessing instruments used in drug discovery and cell-line development. It is a broad incumbent whose cell-analysis portfolio addresses overlapping pharma and biotech customers as Pixel.

TypeBroad incumbent
Description

Bruker's life-science cell-analysis products include high-content imaging and microscopy instruments used by pharma and academic researchers. It is a broad incumbent in analytical cell-biology instrumentation competing for similar R&D dollars.

TypeEmerging player
Description

Standard BioTools produces mass cytometry and single-cell genomics platforms (Helios, Hyperion) for deep cellular profiling. It is an emerging player in high-dimensional single-cell analysis with partial overlap to Pixel's high-parameter, single-cell resolution positioning in pharma research.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytoTronics

Live-Cell Analysis Instrumentscytotronics.com

CytoTronics developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS microelectrode arrays embedded in microplates to deliver label-free, multi-modal cell measurements at single-cell resolution for pharmaceutical, biotech, and academic drug discovery customers, prior to its January 2026 acquisition by Axion BioSystems.

What CytoTronics does

CytoTronics, Inc. was a privately held Boston-based life sciences tools company founded in 2021 as a Harvard University spin-off that developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS (Complementary Metal-Oxide-Semiconductor) microelectrode arrays embedded at the base of standard 96- and 384-well microplates. Each well contained over 100,000 nanoscale electrode-based sensors enabling thousands of simultaneous, label-free, multi-modal measurements (viability, morphology, electrophysiology, metabolism, barrier function) at single-cell resolution, with the company marketing more than 13 million sensors across its plate formats. The product family comprised the entry-level Pixel Primo single-plate reader (starting list price under $30,000), the high-throughput Pixel Octo eight-plate reader with integrated benchtop incubator, proprietary Pixel Plates as recurring consumables, and the cloud-based Pixel Pro control and analysis software, supported by vertical application modules for Neural (April 2025) and Cardiac (May 2025) research.

The company's commercial model combined direct enterprise sales, an early access/Try Before You Buy program, and scientific marketing through conferences (SLAS, ISSCR, Neuroscience), targeting pharmaceutical and biotech drug discovery teams, academic and research institutions, and stem cell/iPSC-derived cell providers, with 40+ collaborator sites across 7 countries by late 2024. CytoTronics raised $22.75M in aggregate seed funding (April 2022 and September 2024) and earned the SLAS 2024 New Product Award and R&D 100 Award in 2024. In January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets, terminating CytoTronics as an independent operating company and rolling the Pixel platform into Axion's existing MEA-focused distribution network.

CytoTronics firmographics

Firmographics
Name
CytoTronics
Legal name
CytoTronics, Inc.
Website
https://cytotronics.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
1–10 employees
Short description
CytoTronics developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS microelectrode arrays embedded in microplates to deliver label-free, multi-modal cell measurements at single-cell resolution for pharmaceutical, biotech, and academic drug discovery customers, prior to its January 2026 acquisition by Axion BioSystems.
Ownership category
akta.pro rank

CytoTronics industry classification

Industry
Product category
Live-Cell Analysis Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Semiconductor and Other Electronic Component Manufacturing (33441)
SIC
Laboratory Analytical Instruments (3826), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAHALAF
Imaging Sensors (CMOS/CCD/ToF/Depth)

Keywords

  • Live-cell analysis
  • CMOS microelectrode arrays
  • Drug discovery platforms
  • Cell biology instruments
  • Electrophysiology imaging

Where CytoTronics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CytoTronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pixel Instruments and Plates: CytoTronics sells Pixel Primo and Pixel Octo instruments along with proprietary Pixel plates (96- and 384-well format) embedded with semiconductor microchips. Starting list price under $30K USD for Pixel Primo.
  2. Software/SaaS (Pixel Pro): Cloud-based Pixel Pro software for control and data analysis, likely offered as subscription or included with hardware purchase

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractPixel Primo entry-level system

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

CytoTronics product offering

Product offering

Core offering

CytoTronics designs and commercializes the Pixel platform — semiconductor-based live-cell analysis systems that integrate CMOS microelectrode arrays into standard 96- and 384-well microplates. The platform includes the Pixel Primo single-plate reader, the Pixel Octo 8-plate high-throughput reader with integrated incubator, proprietary Pixel Plates consumables with over 100,000 nanoscale electrode sensors per well, and cloud-based Pixel Pro software. The system captures 20+ cellular parameters including viability, morphology, electrophysiology, and metabolism simultaneously, enabling drug discovery and cell biology research at single-cell resolution without labels or dyes.

Product overview

CytoTronics offers the Pixel platform, a semiconductor-based live-cell analysis system for cell biology discovery. The core Pixel platform consists of Pixel Primo (entry-level single plate reader starting under $30K) and Pixel Octo (high-throughput 8-plate reader with integrated benchtop incubator), both using proprietary Pixel Plates (96- or 384-well microplates with semiconductor microchips containing over 100,000 nanoscale electrode-based sensors per well). Cloud-based Pixel Pro software enables measurement control and data analysis. The platform delivers simultaneous multi-modal readouts of cell viability, morphology, electrophysiology, metabolism, and barrier function with single-cell resolution via electrical imaging technology. Specialized application modules including Neural Application (for neurological disease and neurotoxicity research) and Cardiac Application (for cardiovascular research and cardiotoxicology) extend the platform for specific therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • Pixel: Semiconductor-based platform for live cell analysis enabling high-resolution monitoring of live cells with single-cell resolution across all cell types. Includes Pixel Primo (single plate reader) and Pixel Octo (8-plate benchtop system).
  • Pixel Pro

Products and services

  • Pixel Primo Entry-level single plate reader for the Pixel platform that fits in any standard cell culture incubator. Reads one 96- or 384-well Pixel plate at a time, enabling semiconductor-based live-cell analysis with thousands of multi-modal measurements per well at single-cell resolution. Targeted at biotech, pharma, and academic researchers.
  • Pixel Octo High-throughput 8-plate reader and benchtop incubator with integrated environmental control for temperature, CO2, humidity, and oxygen. Reads up to eight 96- or 384-well Pixel plates simultaneously and pairs with laboratory robotic automation for industrial-scale screening of tens of thousands of wells in parallel. Targeted at pharma and biotech screening operations.
  • Pixel Plates Proprietary 96- or 384-well microplates embedded with custom-designed semiconductor microchips at the base of each well. Each well contains over 100,000 nanoscale electrode-based sensors enabling thousands of measurements per well on any cell type, spheroid, or 3D organoid system. Consumable used with Pixel Primo and Pixel Octo instruments.
  • Pixel Pro Cloud-based control and interactive analysis software for Pixel systems. Enables measurement design, experiment execution, real-time data access from anywhere, and sophisticated data analysis tools for high-dimensional live cell measurements across viability, morphology, electrophysiology, metabolism, and barrier function.
  • Pixel Neural Application First-of-its-kind application combining electrical imaging with electrophysiology to simultaneously measure neural structure and activity at scale in 96- and 384-well plates with up to 144 recording channels per well. Used for drug discovery in neurological disease, neurotoxicity research, and neurodegenerative disease applications including Parkinson's, Alzheimer's, ALS, and blood-brain barrier studies.
  • Pixel Cardiac Application Multi-modal application measuring cardiomyocyte electrical activity, contractility, and cell morphology simultaneously in a single multiplexed assay at scale in 96- and 384-well plates. Enables cardiovascular disease research and cardiotoxicology studies with real-time monitoring of acute and chronic compound responses.

Quantifiable outcome

  • Captures over 100,000 measurements per well across 20+ cellular parameters
  • +3 more outcomes

Companies that use CytoTronics

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles3 records

CytoTronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

CytoTronics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and flagship.

  • Axol BiosciencecoreStrategic or Co-development PartnerActive collaboration for cell supply in neurodegenerative disease and neurotoxicity research. Axol provides iPSC-derived cells used with Pixel for applications in Parkinson's, Alzheimer's disease, ALS, blood-brain barrier/CNS function, and pain research.
  • AnatomiccoreStrategic or Co-development PartnerActive collaboration for cell and organoid supply requiring sophisticated cell characterization that Pixel enables for disease research.
  • BrainXellcoreStrategic or Co-development PartnerActive collaboration providing neuronal cells for research applications. BrainXell cells used in Pixel applications for neural function studies and blood-brain barrier modeling.
  • Trailhead BiosystemscoreStrategic or Co-development PartnerActive collaboration for organoid supply and disease modeling applications requiring Pixel's cell characterization capabilities.
  • ACROBiosystemscoreStrategic or Co-development PartnerCollaboration site for cardiovascular research and cardiotoxicology applications using Pixel's Cardiac application.
  • FUJIFILM Cellular DynamicscoreStrategic or Co-development PartnerCollaboration providing iPSC-derived cardiomyocytes for cardiac disease modeling and Pixel applications. Human iPSC-derived glutamatergic neurons also used for neural studies.
  • InSpherocoreStrategic or Co-development PartnerCollaboration for 3D cell models (organoids/spheroids) used in cardiotoxicology and disease research with Pixel systems.
  • NcardiacoreStrategic or Co-development PartnerCollaboration for iPSC-derived cells for cardiovascular disease research and cardiac applications using Pixel platform.
  • Stanford UniversitycoreStrategic or Co-development PartnerCollaboration with Dr. Ioannis Karakikes studying cardiac disease phenotypes and genetic mutations in cardiomyopathies. Stanford is part of the international PRIORITY consortium for cardio-laminopathy research.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerCollaboration site for research activities. CytoTronics originated from Harvard University research.
  • Harvard Chemistry & Chemical BiologycoreStrategic or Co-development PartnerCollaboration site for research activities. Original research foundation was developed in Harvard labs.
  • Axion BioSystemsflagshipOEM/ Whitelabel/ Licensing PartnerIn January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets including high-density CMOS MEA technology. Co-founder Jeffrey Abbott transitioned to Vice President at Axion. Axion commercializes the technology through their existing distribution network.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

CytoTronics competitors and assessment

Company assessment

Direct peers

  • Axion BioSystems: Axion BioSystems manufactures multi-well MEA platforms (Maestro) for neural and cardiac activity monitoring. It is the closest direct peer in microplate-format MEA electrophysiology and is now CytoTronics' acquirer, making it both a competitor and commercial vehicle for the Pixel technology.
  • MaxWell Biosystems: MaxWell Biosystems develops high-density CMOS microelectrode array chips (MaxOne, MaxTwo) for single-cell and network-level electrophysiology. It is a direct peer in CMOS-MEA technology for live-cell functional readouts with comparable single-neuron resolution.
  • Multi Channel Systems (Harvard Bioscience): Multi Channel Systems, a Harvard Bioscience company, supplies MEA platforms and MEA-based live-cell recording instruments used in cardiac and neural safety pharmacology. It competes head-to-head with Pixel in microplate-format electrophysiology screening.
  • Nanion Technologies: Nanion Technologies makes planar patch-clamp and MEA instruments for ion-channel research and cardiac safety screening (e.g., CardioExcyte 96). It is a direct peer in electrophysiology instrumentation targeting the same drug-discovery and safety-pharmacology customers.
  • Molecular Devices: Molecular Devices (a Danaher operating company) produces high-content screening imagers and electrophysiology readers used in drug discovery. It overlaps with Pixel in label-free, high-throughput functional cell analysis for pharma research workflows.
  • ACEA Biosciences (xCELLigence, now part of Agilent): ACEA's xCELLigence real-time cell analysis system uses impedance-based readouts in microplate formats to monitor cell viability, morphology, and proliferation. It is a direct competitor in label-free, kinetic live-cell analysis targeting the same drug-discovery and toxicology use cases as Pixel.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher Scientific is a global life-sciences tools incumbent offering cell-analysis instruments, consumables, and informatics. It competes broadly with Pixel through its laboratory products division for pharma and academic research budgets.
  • Sartorius: Sartorius provides cell-analysis and bioprocessing instruments used in drug discovery and cell-line development. It is a broad incumbent whose cell-analysis portfolio addresses overlapping pharma and biotech customers as Pixel.
  • Bruker: Bruker's life-science cell-analysis products include high-content imaging and microscopy instruments used by pharma and academic researchers. It is a broad incumbent in analytical cell-biology instrumentation competing for similar R&D dollars.

Emerging players

  • Standard BioTools (formerly Fluidigm): Standard BioTools produces mass cytometry and single-cell genomics platforms (Helios, Hyperion) for deep cellular profiling. It is an emerging player in high-dimensional single-cell analysis with partial overlap to Pixel's high-parameter, single-cell resolution positioning in pharma research.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CytoTronics social profiles

Digital presence

CytoTronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytoTronics leadership team

Management profile

Number of profiles

Profiles15 records

CytoTronics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytoTronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoTronics

What does CytoTronics do?

CytoTronics designs and commercializes the Pixel platform — semiconductor-based live-cell analysis systems that integrate CMOS microelectrode arrays into standard 96- and 384-well microplates. The platform includes the Pixel Primo single-plate reader, the Pixel Octo 8-plate high-throughput reader with integrated incubator, proprietary Pixel Plates consumables with over 100,000 nanoscale electrode sensors per well, and cloud-based Pixel Pro software. The system captures 20+ cellular parameters including viability, morphology, electrophysiology, and metabolism simultaneously, enabling drug discovery and cell biology research at single-cell resolution without labels or dyes.

Is CytoTronics a public or private company?

CytoTronics is a private company. It is classified as corporate owned and is currently acquired.

When was CytoTronics founded?

CytoTronics was founded in 2021. It employs 1 to 10 people.

Where is CytoTronics based?

CytoTronics is headquartered in Boston, United States, in the North America region.

How does CytoTronics make money?

Two revenue lines are on record. Pixel Instruments and Plates are the primary driver. The others are software/SaaS (Pixel Pro).

Who are CytoTronics's main competitors?

Direct peers on record are Axion BioSystems, MaxWell Biosystems, Multi Channel Systems (Harvard Bioscience), Nanion Technologies, Molecular Devices and ACEA Biosciences (xCELLigence, now part of Agilent). Broad incumbents are Thermo Fisher Scientific, Sartorius and Bruker. Standard BioTools (formerly Fluidigm) is listed as an emerging player.

Does CytoTronics have an API?

No public API is recorded for CytoTronics.

What industry is CytoTronics in?

CytoTronics's product category is Live-Cell Analysis Instruments. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HDAHAAAG, Sensors, MEMS & Imaging ICs. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Axion BioSystems Buys CytoTronics’ High Density CMOS Microelectrode Array Platform For Drug DiscoveryAxion BioSystems has acquired the intellectual property and assets of CytoTronics, gaining high-density CMOS microelectrode array technology originally developed at Harvard University to expand its portfolio of live-cell bioelectronic assay and imaging systems. The deal adds more than 13 million nanoscale, multimodal sensors distributed across 96-well and 384-well microplates, enabling high-throughput screening at single-cell resolution for neural and cardiac drug discovery applications. Axion, founded in 2008 and headquartered in Atlanta, Georgia, with offices in the Netherlands, UK, and China, expects the acquisition to complement its existing MEA and impedance platforms without sacrificing throughput.Business Wire BlogAxion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronicsAxion BioSystems has acquired the intellectual property and assets of CytoTronics, Inc., integrating its high-density CMOS microelectrode array technology into Axion's product suite. This acquisition enables high-throughput, single-cell-level functional screening for disease research and drug discovery using over 13 million nanoscale sensors distributed across standard microplates. The deal positions Axion to commercialize next-generation assays for neural and cardiac applications, leveraging its existing hardware and software infrastructure.SecSEC FORM DThe Securities and Exchange Commission (SEC) has received a notice of exempt offering of securities from CytoTronics, Inc., indicating the issuer's intent to raise $13,500,000. The offering is not related to a business combination transaction and is set to last less than one year, pending regulatory approval.VC News DailyCytoTronics Nabs $13.5M Seed ExtensionCytoTronics announced a $13.5 million seed extension, led by LYFE Capital with Anzu Partners. The company's semiconductor-based platforms provide single-cell resolution for cell biology research and drug development. Sameer Rohatgi of LYFE Capital was appointed to the board.MorningstarCytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell BiologyCytoTronics raised $13.5 million in Series Seed 2 financing led by LYFE Capital, with existing investor Anzu Partners and new investors joining. The funds will accelerate market entry of its Pixel live-cell analysis system, with first product shipments planned for 2025.YahooCytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell BiologyCytoTronics raised $13.5 million in Series Seed 2 financing led by LYFE Capital, with existing investor Anzu Partners and new investors joining. The funds will accelerate market entry of its Pixel live-cell analysis system, with first product shipments planned for 2025.American City Business JournalsHarvard spinout using semiconductors to see cells raises $13.5M seed extension.CytoTronics, a Harvard spinout, raised $13.5 million in a seed extension led by LYFE Capital and Anzu Partners. The company's Pixel plate uses semiconductor microchips to assess live cell functions, and it has 25 early adopters. The team plans to expand manufacturing and customer-facing roles.CytotronicsCytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell BiologyCytoTronics secured a $13.5 million Series Seed 2 financing round led by LYFE Capital with support from existing investor Anzu Partners and other new investors to accelerate the market entry of its Pixel system for cell biology applications. The company also appointed Sameer Rohatgi, a life science industry veteran, to its Board of Directors. This funding will support the expansion of commercial teams and manufacturing as CytoTronics prepares for its first product shipments in 2025.BioSpaceCytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology ApplicationsCytoTronics unveiled its Pixel system at SLAS2024, a semiconductor-based platform for live-cell monitoring at single-cell resolution. The system uses microchips in 96- or 384-well plates to generate multi-modal readouts, with a starting price under $30K. Pixel Octo, a benchtop incubator with an 8-plate reader, will be released later in 2024.Business Wire BlogCytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology ApplicationsCytoTronics revealed its Pixel system at SLAS2024, its first commercial product based on semiconductor-to-live-cell microchips. The system enables simultaneous multi-modal readouts at single-cell resolution, with a starting price under $30K for Pixel Primo. Pixel Octo, a benchtop incubator with an integrated 8-plate reader, will be released later in 2024.